Visitors Now:
Total Visits:
Total Stories:
Profile image
Story Views

Now:
Last Hour:
Last 24 Hours:
Total:

Fragile X Syndrome Therapeutic Pipeline Market Review, H2 2016

Wednesday, October 19, 2016 23:30
% of readers think this story is Fact. Add your two cents.

(Before It's News)

Summary

‘Fragile X Syndrome – Pipeline Review, H2 2016’, provides an overview of the Fragile X Syndrome pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Fragile X Syndrome, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Fragile X Syndrome and features dormant and discontinued projects.

Request a sample report @ https://www.wiseguyreports.com/sample-request/693298-fragile-x-syndrome-pipeline-review-h2-2016

Report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Scope

- The report provides a snapshot of the global therapeutic landscape of Fragile X Syndrome 
- The report reviews pipeline therapeutics for Fragile X Syndrome by companies and universities/research institutes based on information derived from company and industry-specific sources 
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages 
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities 
- The report reviews key players involved Fragile X Syndrome therapeutics and enlists all their major and minor projects 
- The report assesses Fragile X Syndrome therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type 
- The report summarizes all the dormant and discontinued pipeline projects 
- The report reviews latest news related to pipeline therapeutics for Fragile X Syndrome

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies 
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage 
- Identify and understand important and diverse types of therapeutics under development for Fragile X Syndrome
- Identify potential new clients or partners in the target demographic 
- Develop strategic initiatives by understanding the focus areas of leading companies 
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics 
- Devise corrective measures for pipeline projects by understanding Fragile X Syndrome pipeline depth and focus of Indication therapeutics 
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope 
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Make an enquiry before buying this Report @ https://www.wiseguyreports.com/enquiry/693298-fragile-x-syndrome-pipeline-review-h2-2016            

Key points in table of content

Table of Contents 2 
List of Tables 6 
List of Figures 7 
Introduction 8 
Global Markets Direct Report Coverage 8 
Fragile X Syndrome Overview 9 
Therapeutics Development 10 
Pipeline Products for Fragile X Syndrome – Overview 10 
Pipeline Products for Fragile X Syndrome – Comparative Analysis 11 
Fragile X Syndrome – Therapeutics under Development by Companies 12 
Fragile X Syndrome – Therapeutics under Investigation by Universities/Institutes 14 
Fragile X Syndrome – Pipeline Products Glance 15 
Late Stage Products 15 
Clinical Stage Products 16 
Early Stage Products 17 
Fragile X Syndrome – Products under Development by Companies 18 
Fragile X Syndrome – Products under Investigation by Universities/Institutes 20 
Fragile X Syndrome – Companies Involved in Therapeutics Development 21 
Aelis Farma SAS 21 
Alcobra Ltd 22 
AMO Pharma Limited 23 
Anavex Life Sciences Corp. 24 
Confluence Pharmaceuticals LLC 25 
DRI Biosciences Corporation 26 
Eli Lilly and Company 27 
GlaxoSmithKline Plc 28 
GW Pharmaceuticals Plc 29 
Kareus Therapeutics, SA 30 
Marinus Pharmaceuticals, Inc. 31 
Neuren Pharmaceuticals Limited 32 
Neuron Biopharma SA 33 
Ovid Therapeutics Inc. 34 
Sage Therapeutics, Inc. 35 
Zynerba Pharmaceuticals, Inc. 36 
Fragile X Syndrome – Therapeutics Assessment 37 
Assessment by Monotherapy Products 37 
Assessment by Target 38 
Assessment by Mechanism of Action 40 
Assessment by Route of Administration 42 
Assessment by Molecule Type 44 
Drug Profiles 46 
acamprosate calcium – Drug Profile 46 
Product Description 46 
Mechanism Of Action 46 
R&D Progress 46 
ACT-01 – Drug Profile 47 
Product Description 47 
Mechanism Of Action 47 
R&D Progress 47 
AMO-01 – Drug Profile 48 
Product Description 48 
Mechanism Of Action 48 
R&D Progress 48 
ANAVEX-273 – Drug Profile 49 
Product Description 49 
Mechanism Of Action 49 
R&D Progress 49 
Bryostatin-1 – Drug Profile 57 
Product Description 57 
Mechanism Of Action 57 
R&D Progress 57 
cercosporamide – Drug Profile 61 
Product Description 61 
Mechanism Of Action 61 
R&D Progress 61 
Drug to Antagonize mGluR5 for Fragile X Syndrome and 16p11.2 Microdeletion Syndrome – Drug Profile 62 
Product Description 62 
Mechanism Of Action 62 
R&D Progress 62 
flindokalner – Drug Profile 63 
Product Description 63 
Mechanism Of Action 63 
R&D Progress 63 
gaboxadol – Drug Profile 64 
Product Description 64 
Mechanism Of Action 64 
R&D Progress 64 
ganaxolone – Drug Profile 66 
Product Description 66 
Mechanism Of Action 66 
R&D Progress 66 
JRP-655 – Drug Profile 71 
Product Description 71 
Mechanism Of Action 71 
R&D Progress 71 
KU-046 – Drug Profile 72 
Product Description 72 
Mechanism Of Action 72 
R&D Progress 72 
metadoxine ER – Drug Profile 73 
Product Description 73 
Mechanism Of Action 73 
R&D Progress 73 
NNZ-2591 – Drug Profile 79 
Product Description 79 
Mechanism Of Action 79 
R&D Progress 79 
NST-0076 – Drug Profile 81 
Product Description 81 
Mechanism Of Action 81 
R&D Progress 81 
SGE-872 – Drug Profile 82 
Product Description 82 
Mechanism Of Action 82 
R&D Progress 82 
Small Molecule for Fragile X-Associated Tremor Ataxia Syndrome – Drug Profile 83 
Product Description 83 
Mechanism Of Action 83 
R&D Progress 83 
Small Molecule to Activate FMRP for Fragile X Syndrome – Drug Profile 84 
Product Description 84 
Mechanism Of Action 84 
R&D Progress 84 
Small Molecule to Antagonize CB1R for Fragile X Syndrome and Down Syndrome – Drug Profile 85 
Product Description 85 
Mechanism Of Action 85 
R&D Progress 85 
Small Molecules to Activate Slack Channels for Fragile X Syndrome – Drug Profile 86 
Product Description 86 
Mechanism Of Action 86 
R&D Progress 86 
Small Molecules to Agonize Cannabinoid Receptor 2 for Fragile X Syndrome, Pervasive Developmental Disorder and Rett Syndrome – Drug Profile 87 
Product Description 87 
Mechanism Of Action 87 
R&D Progress 87 
Small Molecules to Block Kv3.1 for Fragile X Syndrome – Drug Profile 88 
Product Description 88 
Mechanism Of Action 88 
R&D Progress 88 
Small Molecules to Inhibit PI3K for Autism and Fragile X Syndrome – Drug Profile 89 
Product Description 89 
Mechanism Of Action 89 
R&D Progress 89 
SRT-278 – Drug Profile 90 
Product Description 90 
Mechanism Of Action 90 
R&D Progress 90 
TC-2153 – Drug Profile 91 
Product Description 91 
Mechanism Of Action 91 
R&D Progress 91 
trofinetide – Drug Profile 92 
Product Description 92 
Mechanism Of Action 92 
R&D Progress 92 
ZYN-002 – Drug Profile 98 
Product Description 98 
Mechanism Of Action 98 
R&D Progress 98 
Fragile X Syndrome – Dormant Projects 101 
Fragile X Syndrome – Discontinued Products 103 
Fragile X Syndrome – Product Development Milestones 104 
Featured News & Press Releases 104 
Jul 19, 2016: Alcobra Granted European Orphan Drug Designation for Metadoxine in Fragile X Syndrome 104 
Jun 28, 2016: Results from Phase 2 Exploratory Clinical Study Support Continued Development of Ganaxolone in Fragile X Syndrome 104 
Jun 27, 2016: Marinus Pharmaceuticals to Host Conference Call on Tuesday, June 28 105 
Jun 27, 2016: Zynerba Pharmaceuticals Announces Positive Top Line Results from ZYN002 CBD Gel Phase 1 Multiple Rising Dose Trial and Initiation of Phase 2 Study in Adult Epilepsy Patients with Refractory Focal Seizures 106 
Jun 22, 2016: Neuren receives grant of new Australian patent for trofinetide to treat Autism Spectrum Disorders 107 
Jun 21, 2016: Bryostatin, a PKC epsilon Activator, Generates New Synapses Through Accumulation of the Synaptic Anchoring Protein PSD-95 at Neuronal Membranes 107 
Jun 13, 2016: Neurotrope’s Chief Scientific Officer Dr. Daniel Alkon Presents at the Gordon Conference: Drugs That Target Common Mechanisms for Synaptic Restoration in Mental Retardation and Alzheimer’s Disease 108 
Jun 07, 2016: AMO Pharma Presents Pre-clinical Data Showing AMO-01 Successfully Inhibits Activated Pathway Associated with Fragile X Syndrome 108 
Jun 06, 2016: Anavex Announces Positive Preclinical Results with ANAVEX 2-73 in Fragile X – Autism-Related Disorders 109 
Apr 12, 2016: Cannabis and Cannabinoid Research Publishes Data Demonstrating the Degradation of Cannabidiol to Psychoactive Cannabinoids when Exposed to Simulated Gastric Fluid 110 
Mar 08, 2016: Neurotrope Announces Publication Demonstrating Synaptic Regeneration with the PKC epsilon Activator Bryostatin, in a Fragile X Disease Late Brain Development Model 111 
Feb 25, 2016: Zynerba Pharmaceuticals Announces ZYN002 Granted Orphan Drug Designation for Fragile X Syndrome 111 
Jan 06, 2016: Zynerba Pharmaceuticals Announces Positive Initial Results From ZYN002 CBD Gel Phase 1 Single Rising Dose Trial and Initiation of Phase 1 Multiple Rising Dose Trial 112 
Dec 07, 2015: Neuren’s trofinetide successful in proof of concept Phase 2 clinical trial in Fragile X syndrome 113 
Nov 30, 2015: Neuren receives grant of composition patent in Europe for NNZ-2591 115 
Appendix 116 
Methodology 116 
Coverage 116 
Secondary Research 116 
Primary Research 116 
Expert Panel Validation 116 
Contact Us 116 
Disclaimer 117

List of Tables 
Number of Products under Development for Fragile X Syndrome, H2 2016 10 
Number of Products under Development for Fragile X Syndrome – Comparative Analysis, H2 2016 11 
Number of Products under Development by Companies, H2 2016 13 
Number of Products under Investigation by Universities/Institutes, H2 2016 14 
Comparative Analysis by Late Stage Development, H2 2016 15 
Comparative Analysis by Clinical Stage Development, H2 2016 16 
Comparative Analysis by Early Stage Development, H2 2016 17 
Products under Development by Companies, H2 2016 18 
Products under Development by Companies, H2 2016 (Contd..1) 19 
Products under Investigation by Universities/Institutes, H2 2016 20 
Fragile X Syndrome – Pipeline by Aelis Farma SAS, H2 2016 21 
Fragile X Syndrome – Pipeline by Alcobra Ltd, H2 2016 22 
Fragile X Syndrome – Pipeline by AMO Pharma Limited, H2 2016 23 
Fragile X Syndrome – Pipeline by Anavex Life Sciences Corp., H2 2016 24 
Fragile X Syndrome – Pipeline by Confluence Pharmaceuticals LLC, H2 2016 25 
Fragile X Syndrome – Pipeline by DRI Biosciences Corporation, H2 2016 26 
Fragile X Syndrome – Pipeline by Eli Lilly and Company, H2 2016 27 
Fragile X Syndrome – Pipeline by GlaxoSmithKline Plc, H2 2016 28 
Fragile X Syndrome – Pipeline by GW Pharmaceuticals Plc, H2 2016 29 
Fragile X Syndrome – Pipeline by Kareus Therapeutics, SA, H2 2016 30 
Fragile X Syndrome – Pipeline by Marinus Pharmaceuticals, Inc., H2 2016 31 
Fragile X Syndrome – Pipeline by Neuren Pharmaceuticals Limited, H2 2016 32 
Fragile X Syndrome – Pipeline by Neuron Biopharma SA, H2 2016 33 
Fragile X Syndrome – Pipeline by Ovid Therapeutics Inc., H2 2016 34 
Fragile X Syndrome – Pipeline by Sage Therapeutics, Inc., H2 2016 35 
Fragile X Syndrome – Pipeline by Zynerba Pharmaceuticals, Inc., H2 2016 36 
Assessment by Monotherapy Products, H2 2016 37 
Number of Products by Stage and Target, H2 2016 39 
Number of Products by Stage and Mechanism of Action, H2 2016 41 
Number of Products by Stage and Route of Administration, H2 2016 43 
Number of Products by Stage and Molecule Type, H2 2016 45 
Fragile X Syndrome – Dormant Projects, H2 2016 101 
Fragile X Syndrome – Dormant Projects (Contd..1), H2 2016 102 
Fragile X Syndrome – Discontinued Products, H2 2016 103

Get this report @ https://www.wiseguyreports.com/checkout?currency=one_user-USD&report_id=693298

 

Contact US:

NORAH TRENT

Partner Relations & Marketing Manager

sales@wiseguyreports.com

Ph: +1-646-845-9349 (US)

Ph: +44 208 133 9349 (UK)           

Report abuse

Comments

Your Comments
Question   Razz  Sad   Evil  Exclaim  Smile  Redface  Biggrin  Surprised  Eek   Confused   Cool  LOL   Mad   Twisted  Rolleyes   Wink  Idea  Arrow  Neutral  Cry   Mr. Green

Top Stories
Recent Stories

Register

Newsletter

Email this story
Email this story

If you really want to ban this commenter, please write down the reason:

If you really want to disable all recommended stories, click on OK button. After that, you will be redirect to your options page.